Thank you, Mr. Chair.
My question will be in French, if you don't mind.
I have prepared a number of questions, but in going over your presentation, some others came to mind.
Everyone is in favour of reducing drug prices and improving access to better drugs. You said there were some very simple solutions that could be used to bring down prices. There may be a lack of dialogue or a lack of consistency, if you will, around drug pricing or regulation. If the solutions are so simple, why hasn't it been possible to come to some agreement prior to now? What are the previous pitfalls attributable to? The committee's examination presents us with an opportunity to talk about that. What were the first pitfalls due to?